143 related articles for article (PubMed ID: 26744910)
1. Influences of teriparatide administration on marrow fat content in postmenopausal osteopenic women using MR spectroscopy.
Yang Y; Luo X; Xie X; Yan F; Chen G; Zhao W; Jiang Z; Fang C; Shen J
Climacteric; 2016 Jun; 19(3):285-91. PubMed ID: 26744910
[TBL] [Abstract][Full Text] [Related]
2. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
[TBL] [Abstract][Full Text] [Related]
3. Teriparatide's effects on quantitative ultrasound parameters and bone density in women with established osteoporosis.
Gonnelli S; Martini G; Caffarelli C; Salvadori S; Cadirni A; Montagnani A; Nuti R
Osteoporos Int; 2006 Oct; 17(10):1524-31. PubMed ID: 16767526
[TBL] [Abstract][Full Text] [Related]
4. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial.
Leder BZ; Tsai JN; Neer RM; Uihlein AV; Wallace PM; Burnett-Bowie SA
J Clin Densitom; 2016; 19(3):346-51. PubMed ID: 26900146
[TBL] [Abstract][Full Text] [Related]
5. Effect of zoledronic acid on vertebral marrow adiposity in postmenopausal osteoporosis assessed by MR spectroscopy.
Yang Y; Luo X; Yan F; Jiang Z; Li Y; Fang C; Shen J
Skeletal Radiol; 2015 Oct; 44(10):1499-505. PubMed ID: 26130070
[TBL] [Abstract][Full Text] [Related]
6. Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis.
Gossiel F; Scott JR; Paggiosi MA; Naylor KE; McCloskey EV; Peel NFA; Walsh JS; Eastell R
J Clin Endocrinol Metab; 2018 Apr; 103(4):1302-1309. PubMed ID: 29365099
[TBL] [Abstract][Full Text] [Related]
7. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
8. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.
Anastasilakis AD; Polyzos SA; Makras P; Gkiomisi A; Bisbinas I; Katsarou A; Filippaios A; Mantzoros CS
Osteoporos Int; 2014 May; 25(5):1633-42. PubMed ID: 24599275
[TBL] [Abstract][Full Text] [Related]
9. Magnetic Resonance Spectroscopy for Evaluating the Effect of Pulsed Electromagnetic Fields on Marrow Adiposity in Postmenopausal Women With Osteopenia.
Li S; Jiang H; Wang B; Gu M; Bi X; Yin Y; Wang Y
J Comput Assist Tomogr; 2018; 42(5):792-797. PubMed ID: 29901507
[TBL] [Abstract][Full Text] [Related]
10. Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study.
Minne H; Audran M; Simões ME; Obermayer-Pietsch B; Sigurðsson G; Marín F; Dalsky GP; Nickelsen T;
Curr Med Res Opin; 2008 Nov; 24(11):3117-28. PubMed ID: 18838053
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
13. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
14. Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis.
Hwang JS; Tu ST; Yang TS; Chen JF; Wang CJ; Tsai KS
Osteoporos Int; 2006; 17(3):373-8. PubMed ID: 16421647
[TBL] [Abstract][Full Text] [Related]
15. Once-weekly teriparatide reduces serum sclerostin levels in postmenopausal women with osteoprosis.
Ikeda T; Kaji H; Tamura Y; Akagi M
J Orthop Sci; 2019 May; 24(3):532-538. PubMed ID: 30573396
[TBL] [Abstract][Full Text] [Related]
16. Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial.
Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Koukoulis GN; Efstathiadou Z; Kita M; Avramidis A
Int J Clin Pract; 2008 Jun; 62(6):919-24. PubMed ID: 18422590
[TBL] [Abstract][Full Text] [Related]
17. The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study.
Creatsa M; Pliatsika P; Kaparos G; Antoniou A; Armeni E; Tsakonas E; Panoulis C; Alexandrou A; Dimitraki E; Christodoulakos G; Lambrinoudaki I
J Obstet Gynaecol Res; 2011 Oct; 37(10):1415-22. PubMed ID: 21651652
[TBL] [Abstract][Full Text] [Related]
18. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
[TBL] [Abstract][Full Text] [Related]
19. Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis.
Cohen A; Kamanda-Kosseh M; Recker RR; Lappe JM; Dempster DW; Zhou H; Cremers S; Bucovsky M; Stubby J; Shane E
J Clin Endocrinol Metab; 2015 Nov; 100(11):4208-14. PubMed ID: 26358172
[TBL] [Abstract][Full Text] [Related]
20. Association of serum sclerostin levels with marrow adiposity in postmenopausal women with glucocorticoid-induced osteoporosis.
Li W; Wang W; Zhang M; Chen Q; Li F; Li S
BMC Endocr Disord; 2024 Apr; 24(1):55. PubMed ID: 38679740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
